Pay in 4 interest-free payments of $7.43 Learn more
Ships within 48 hours · Estimated delivery Sep 25 - Sep 30
Ganz einfach, Du hast uns verboten Deine Nutzung auf unserer Seite mit Google Analytics zu beobachten
Neurology/Psychiatric July 12, 2023 Novartis AG has described pyridine-3-carboxylate compounds acting as voltage-dependent L-type calcium channel subunit -1C channel (Cav1.2) activators reported to be useful for the treatment of schizophrenia, major depression, attention deficit hyperactivity disorder, autism spectrum disorder, multiple sclerosis, frontotemporal dementia, Alzheimers disease and Brugada syndrome
Telehealth consultation fees are separate and vary widely
Register now
US$ 29.02
US$ 23.11
US$ 20.27
US$ 21.19
